dfda compounded glp-1 receptor agonists ban: What providers need to know FDA is moving to restrict

Nearly 20% of sites prescribed #GLP-1 receptor agonists based on upper-body photos alone

Tirzepatide displayed an unprecedented glucose and body weight lowering potential, presenting also with the ability to increase insulin sensitivity, reduce systolic blood pressure and inflammation and ameliorate dyslipidemia, particularly by reducing triglycerides levels

95% CI 0.35, 3.14)

Discover how once-monthly maridebart cafraglutide for the treatment of obesity works, its clinical trial evidence, potential eligibility criteria, side effects, and the pathway to NHS access if approved by UK regulators.

Explore BPS Biosciences solutions for GLP-1R research in diabetes

The recently initiated large-sized FLOW trial investigating the effects of semaglutide on hard renal outcomes in patients with DKD will provide clarity whether GLP-1 receptor agonists may reduce the burden of DKD in addition to their other beneficial metabolic and cardiovascular effects.